90 research outputs found
Foxg1 and Emx2 control of cortico-cerebral astrogenesis and Emx2 as a novel tool to suppress glioblastoma multiforme
Cortico--‐cerebral astrogenesis is a tightly regulated process. Astrocytic outputs mainly depend on two factors: progression of multipotent precursors towards the astroglial
lineage and sizing of the astrogenic proliferating pool.
Uncontrolled proliferation of astroglial cells in adult may give rise to severe pathologies,
such as glioblastoma multiforme (GBM), for which no cure is presently available. The
aim of this study was to study the role of two transcription factors, Foxg1 and Emx2,
in the regulation of mouse corticocerebral astrogenesis and to employ Emx2 as a possible
therapeutical tool to counteract GBM. We addressed this issue by combined gain-and loss--of--‐function methods, in vivo as well as in primary cultures of cortico—cerebral precursors
and of patients’ GBM cell lines. We found that Foxg1antagonizes the commitment of early
neural stem cells toward glial fate, while Emx2 suppress the proliferation of astrocyte—committed progenitors.
We showed that Foxg1 inhibits the transcription of the well-‐known glial gene Gfap, possibly
by impacting the regulation of the gliogenic transactive pathways.
Then, we found that Emx2 overexpression in cortico--‐cerebral stem cells shrunk the proliferating astrogenic pool, resulting in a severe reduction of the astroglial outcome.
We showed that this was caused by EgfR and Fgf9 downregulation and that both phenomena
originated from exaggerated Bmp signaling and Sox2 repression. Furthermore, we provided
evidence that in vivo temporal progression of Emx2 levels in cortico--‐cerebral multipotent
precursors contributes to confine the bulk of astrogenesis to postnatal life. Finally, we translated our findings on Emx2 role in the normal astrogenesis to a possible gene therapy
to suppress glioblastoma multiforme tumor.
As for this last part of the study, we investigated the impact of Emx2 overexpression on patient malignant cells in vitro as well as upon transplantation into mouse recipient brains.
We discovered that Emx2 overexpression induced the collapse of seven out of seven in vitro
tested glioblastoma cell lines.
Moreover, it suppressed four out of four of these lines in vivo in short--‐term approaches
and it also increased the survival of GBM--‐transplanted mice in a long--‐term experiment.
As proven by dedicated rescue assays, the anti--‐oncogenic activity of Emx2 originated from
its impact on at least six metabolic nodes, which accounts for the robustness of its effect.
Finally, in two out of two tested lines, the tumor culture collapse was also achieved when
Emx2 was driven by a neural stem cell--‐specific promoter, likely active within tumor--‐initiating cells. All that points to Emx2 as a novel, promising tool for therapy of glioblastoma
and prevention of its recurrencies
FoxG1 antagonizes neocortical stem cell progression to astrogenesis
Neocortical astrogenesis follows neuronogenesis and precedes oligogenesis. Among key factors dictating its temporal articulation, there are progression rates of pallial stem cells (SCs) towards astroglial lineages as well as activation rates of astrocyte differentiation programs in response to extrinsic gliogenic cues. In this study, we showed that high Foxg1 SC expression antagonizes astrocyte generation, while stimulating SC self-renewal and committing SCs to neuronogenesis. We found that mechanisms underlying this activity are mainly cell autonomous and highly pleiotropic. They include a concerted downregulation of 4 key effectors channeling neural SCs to astroglial fates, as well as defective activation of core molecular machineries implementing astroglial differentiation programs. Next, we found that SC Foxg1 levels specifically decline during the neuronogenic-to-gliogenic transition, pointing to a pivotal Foxg1 role in temporal modulation of astrogenesis. Finally, we showed that Foxg1 inhibits astrogenesis from human neocortical precursors, suggesting that this is an evolutionarily ancient trait
Use of Agro-Waste as a Source of Crop Nutrients in Intensive Horticulture System
The inadequate management of agro-waste in intensive agriculture has a severe negative impact on the environment. The valorization of crop residue as a source of crop nutrients is a valid alternative to close the nutrient cycle and reduce the use of external input. In this study, plant material was incorporated into the soil as fresh crop residue, after either composting and vermicomposting processes, to evaluate their effects on tomato yield and nutritional status (petiole sap analysis: NO3 and K+ concentration) over three crop cycles. A control treatment with mineral fertigation and an organic control treatment with goat manure were also included. Enzymatic activity and microbial population in the soil were evaluated. Although no differences between treatments were observed in the first cycle, in the second and third cycles, the yield obtained with the application of organic amendments derived from agro-waste was comparable to the yield obtained with mineral fertilizers. Overall, the sap analysis did not reveal a clear relationship with yield performances. The compost treatment resulted in higher microorganism presence in the soil. Soil dehydrogenase activity (DHA), acid phosphatase activity (ACP), and β-glucosidase activity (β-GLU) were generally more stimulated when organic amendments were used. The study confirms the applicability of soil fertilizers derived from agro-waste as a good alternative to mineral fertilizers
Population Growth in Major Mountain West Metros, 2010 - 2019
On March 26, 2020, the U.S. Census Bureau released population estimates for the time period between July 2010 and July 2019. Brookings senior fellow, William H. Frey suggests that “Even before coronavirus, census shows U.S. cities’ growth was stagnating.” This fact sheet explores population growth trends in 5 Mountain West Metropolitan Statistical Areas (MSA) with populations over one million residents (i.e. Phoenix, Denver, Las Vegas, Salt Lake City, and Tucson)
The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres
BACKGROUND This study aimed to calculate costs and health-related quality of life of women with endometriosis-associated symptoms treated in referral centres. METHODS A prospective, multi-centre, questionnaire-based survey measured costs and quality of life in ambulatory care and in 12 tertiary care centres in 10 countries. The study enrolled women with a diagnosis of endometriosis and with at least one centre-specific contact related to endometriosis-associated symptoms in 2008. The main outcome measures were health care costs, costs of productivity loss, total costs and quality-adjusted life years. Predictors of costs were identified using regression analysis. RESULTS Data analysis of 909 women demonstrated that the average annual total cost per woman was €9579 (95% confidence interval €8559-€10 599). Costs of productivity loss of €6298 per woman were double the health care costs of €3113 per woman. Health care costs were mainly due to surgery (29%), monitoring tests (19%) and hospitalization (18%) and physician visits (16%). Endometriosis-associated symptoms generated 0.809 quality-adjusted life years per woman. Decreased quality of life was the most important predictor of direct health care and total costs. Costs were greater with increasing severity of endometriosis, presence of pelvic pain, presence of infertility and a higher number of years since diagnosis. CONCLUSIONS Our study invited women to report resource use based on endometriosis-associated symptoms only, rather than drawing on a control population of women without endometriosis. Our study showed that the economic burden associated with endometriosis treated in referral centres is high and is similar to other chronic diseases (diabetes, Crohn's disease, rheumatoid arthritis). It arises predominantly from productivity loss, and is predicted by decreased quality of lif
Geographical variation in therapy for bloodstream infections due to multidrug-resistant enterobacteriaceae: a post hoc analysis of the INCREMENT study
We aimed to describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). 1,482 patients in 12 countries were included from an observational study of BSI caused by ESBL-E or CPE. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of ?-lactam/?-lactamase inhibitors (BLBLI) or carbapenems, targeted use of BLBLI for ESBL-E and use of targeted combination therapy for CPE. The use of BLBLI for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14-0.81), Greece (aOR 0.49, 95% CI 0.26-0.94) and Canada (aOR 0.31, 95% CI 0.11-0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11-2.2) and Turkey (aOR 2.09, 95% CI 1.14-3.81), compared to Spain as a reference. Empirical carbapenems were more likely to be used in sites from Taiwan (aOR 1.73, 95% CI 1.03-2.92) and USA (aOR 1.89; 95% CI 1.05-3.39), and less likely in Italy (aOR 0.44, 95% CI 0.28-0.69) and Canada (aOR 0.10, 95% CI 0.01-0.74). Targeted BLBLI for ESBL-E was more likely in sites from Italy. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. A better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts.PH is supported by an Australian Postgraduate Award from the University of
Queensland. The study was funded by the Ministerio de Economía y Competitividad,
Instituto de Salud Carlos III - co-financed by European Development Regional Fund "A way to
achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI
RD12/0015). BGG, JRB, APH and YC also received funds from the COMBACTE-CARE
project (grant agreement 115620), Innovative Medicines Initiative (IMI), the European
Union's Seventh Framework Programme (FP7/2007-2013) and in-kind contributions from
EFPIA companies
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males
The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3L412F-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways. Abbreviations: AP: autophagosome; AUC: area under the curve; BafA1: bafilomycin A1; COVID-19: coronavirus disease-2019; HCQ: hydroxychloroquine; RAP: rapamycin; ROC: receiver operating characteristic; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TLR: toll like receptor; TNF/TNF-α: tumor necrosis factor
How future surgery will benefit from SARS-COV-2-related measures: a SPIGC survey conveying the perspective of Italian surgeons
COVID-19 negatively affected surgical activity, but the potential benefits resulting from adopted measures remain unclear. The aim of this study was to evaluate the change in surgical activity and potential benefit from COVID-19 measures in perspective of Italian surgeons on behalf of SPIGC. A nationwide online survey on surgical practice before, during, and after COVID-19 pandemic was conducted in March-April 2022 (NCT:05323851). Effects of COVID-19 hospital-related measures on surgical patients' management and personal professional development across surgical specialties were explored. Data on demographics, pre-operative/peri-operative/post-operative management, and professional development were collected. Outcomes were matched with the corresponding volume. Four hundred and seventy-three respondents were included in final analysis across 14 surgical specialties. Since SARS-CoV-2 pandemic, application of telematic consultations (4.1% vs. 21.6%; p < 0.0001) and diagnostic evaluations (16.4% vs. 42.2%; p < 0.0001) increased. Elective surgical activities significantly reduced and surgeons opted more frequently for conservative management with a possible indication for elective (26.3% vs. 35.7%; p < 0.0001) or urgent (20.4% vs. 38.5%; p < 0.0001) surgery. All new COVID-related measures are perceived to be maintained in the future. Surgeons' personal education online increased from 12.6% (pre-COVID) to 86.6% (post-COVID; p < 0.0001). Online educational activities are considered a beneficial effect from COVID pandemic (56.4%). COVID-19 had a great impact on surgical specialties, with significant reduction of operation volume. However, some forced changes turned out to be benefits. Isolation measures pushed the use of telemedicine and telemetric devices for outpatient practice and favored communication for educational purposes and surgeon-patient/family communication. From the Italian surgeons' perspective, COVID-related measures will continue to influence future surgical clinical practice
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues
Variability in SARS-CoV-2 susceptibility and COVID-19 disease severity between individuals is partly due to
genetic factors. Here, we identify 4 genomic loci with suggestive associations for SARS-CoV-2 susceptibility
and 19 for COVID-19 disease severity. Four of these 23 loci likely have an ethnicity-specific component.
Genome-wide association study (GWAS) signals in 11 loci colocalize with expression quantitative trait loci
(eQTLs) associated with the expression of 20 genes in 62 tissues/cell types (range: 1:43 tissues/gene),
including lung, brain, heart, muscle, and skin as well as the digestive system and immune system. We perform
genetic fine mapping to compute 99% credible SNP sets, which identify 10 GWAS loci that have eight or fewer
SNPs in the credible set, including three loci with one single likely causal SNP. Our study suggests that the
diverse symptoms and disease severity of COVID-19 observed between individuals is associated with variants across the genome, affecting gene expression levels in a wide variety of tissue types
- …